

ARRAY BIOPHARMA INC
Form 10-Q
February 05, 2007

U.S. SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended December 31, 2006

or

TRANSITION REPORT UNDER SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from _____ to _____

Commission File Number: 000-31979

Array BioPharma Inc.

(Exact Name of Registrant as Specified in Its Charter)

Delaware

(State or Other Jurisdiction of
Incorporation or Organization)

84-1460811

(I.R.S. Employer Identification No.)

3200 Walnut Street, Boulder, CO

(Address of Principal Executive Offices)

80301

(Zip Code)

(303) 381-6600

(Registrant's Telephone Number, Including Area Code)

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, or a non-accelerated filer. See definition of accelerated filer and large accelerated filer in Rule 12b-2 of the Exchange Act.

(Check one): Large Accelerated Filer Accelerated Filer Non-Accelerated Filer

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).

For the quarterly period ended December 31, 2006

Edgar Filing: ARRAY BIOPHARMA INC - Form 10-Q

Yes No

As of January 31, 2007, the registrant had 39,937,518 shares of common stock, par value \$.001 per share, outstanding.

ARRAY BIOPHARMA INC.

TABLE OF CONTENTS

	PAGE
<u>PART I - FINANCIAL INFORMATION</u>	
<u>Item 1.</u>	<u>Condensed Financial Statements</u>
	<u>Balance Sheets at December 31, 2006 and June 30, 2006 (unaudited)</u> 3
	<u>Statements of Operations Three and Six Months Ended December 31, 2006 and 2005 (unaudited)</u> 4
	<u>Statements of Cash Flows Six Months Ended December 31, 2006 and 2005 (unaudited)</u> 5
	<u>Notes to Condensed Financial Statements (unaudited)</u> 6
<u>Item 2.</u>	<u>Management's Discussion and Analysis of Financial Condition and Results of Operations</u> 13
<u>Item 3.</u>	<u>Quantitative and Qualitative Disclosures About Market Risk</u> 21
<u>Item 4.</u>	<u>Controls and Procedures</u> 21
<u>PART II - OTHER INFORMATION</u>	
<u>Item 4.</u>	<u>Submission of Matters to a Vote of Security Holders</u> 22
<u>Item 6.</u>	<u>Exhibits</u> 22
<u>SIGNATURES</u>	23

PART I

Item 1. Financial Statements

ARRAY BIOPHARMA INC.
CONDENSED BALANCE SHEETS

(Unaudited)

(In thousands)

	December 31, 2006	June 30, 2006
ASSETS		
Current assets		
Cash and cash equivalents	\$ 17,039	\$ 15,568
Marketable securities	67,361	54,532
Accounts receivable, net	370	1,359
Inventories, net	1,550	1,645
Prepaid expenses and other	2,072	1,760
Total current assets	88,392	74,864
Property, plant and equipment	68,245	66,139
Less accumulated depreciation and amortization	(42,023)	(38,830)
Property, plant and equipment, net	26,222	27,309
Total assets	\$ 114,614	\$ 102,173
LIABILITIES AND STOCKHOLDERS EQUITY		
Current liabilities		
Accounts payable	\$ 5,813	\$ 6,212
Advance payments from collaborators - current	6,683	3,800
Accrued compensation and benefits	3,428	5,770
Deferred rent - current	2,661	1,563
Other current liabilities	1,587	1,511
Total current liabilities	20,172	18,856
Advance payments from collaborators - long term	53	78
Deferred rent - long term	28,511	
Long term debt	15,000	14,150
Other long term liabilities	593	448
Total liabilities	64,329	33,532
Stockholders' equity		
Preferred stock		
Common stock	40	39
Additional paid-in capital	208,052	202,526
Accumulated other comprehensive loss	(50)	(270)

For the quarterly period ended December 31, 2006

Edgar Filing: ARRAY BIOPHARMA INC - Form 10-Q

Accumulated deficit	(157,757)	(133,654)
Total stockholders' equity	50,285	68,641
Total liabilities and stockholders' equity	\$ 114,614	\$ 102,173

See notes to condensed financial statements

3

ARRAY BIOPHARMA INC.

CONDENSED STATEMENTS OF OPERATIONS

(Unaudited)

(In thousands, except per share data)

	Three Months Ended December 31,		Six Months Ended December 31,	
	2006	2005	2006	2005
Revenue				
Collaboration revenue	\$ 7,546	\$ 9,232	\$ 15,535	\$ 17,515
License and milestone revenue	12	2,708	3,049	5,667
Total revenue	7,558	11,940	18,584	23,182
Operating expenses				
Cost of revenue	6,218	10,013	12,485	19,403
Research and development for proprietary drug discovery	14,785	7,802	25,638	16,427
Selling, general and administrative expenses	3,283	3,379	6,252	6,833
Total operating expenses	24,286	21,194	44,375	42,663
Loss from operations	(16,728)	(9,254)	(25,791)	(19,481)
Interest expense	(249)	(153)	(489)	(282)
Interest income	1,105	696	2,177	1,380
Net loss	\$ (15,872)	\$ (8,711)	\$ (24,103)	\$ (18,383)
Basic and diluted net loss per share	\$ (0.40)	\$ (0.23)	\$ (0.61)	\$ (0.48)
Number of shares used to compute per share data	39,471	38,617	39,309	38,557

See notes to condensed financial statements

ARRAY BIOPHARMA INC.

CONDENSED STATEMENTS OF CASH FLOWS

(Unaudited)

(In thousands)

	Six Months Ended December 31,	
	2006	2005
Operating activities		
Net loss	\$ (24,103)	\$ (18,383)
Adjustments to reconcile net loss to net cash used in operating activities:		
Depreciation and amortization	3,201	4,627
Share-based compensation expense	2,393	3,411
Deferred rent (credits) charges	(2,666)	58
Changes in operating assets and liabilities	1,111	(5,491)
Net cash used in operating activities	(20,064)	(15,778)
Investing activities		
Purchases of property, plant and equipment	(2,116)	(2,414)
Purchases of marketable securities	(45,408)	(34,885)
Proceeds from sale and maturity of marketable securities	32,800	47,725
Net proceeds from assignment of facility purchase options	32,275	
Decrease in restricted cash		1,980
Net cash provided by investing activities	17,551	12,406
Financing activities		
Proceeds from exercise of stock options and shares issued under the employee stock purchase plan	3,134	695
Proceeds from the issuance of long term debt	850	2,553
Net cash provided by financing activities	3,984	3,248
Net increase (decrease) in cash and cash equivalents	1,471	(124)
Cash and cash equivalents, beginning of period	15,568	12,430
Cash and cash equivalents, end of period	\$ 17,039	\$ 12,306

Supplemental disclosure of cash flow information

Cash paid for interest was \$476 and \$227 for the six months ended December 31, 2006 and 2005, respectively.

See notes to condensed financial statements

ARRAY BIOPHARMA INC.

NOTES TO CONDENSED FINANCIAL STATEMENTS

December 31, 2006

(Unaudited)

(In thousands, except share and per share data, unless otherwise noted)

Note 1: Basis of Presentation and Summary of Significant Accounting Policies

Interim Financial Statements

The accompanying unaudited condensed financial statements have been prepared in accordance with accounting principles generally accepted in the United States and with the instructions to Form 10-Q and Article 10 of Regulation S-X for interim financial information. Accordingly, they do not include all of the information and footnotes required by accounting principles generally accepted in the United States for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation have been included. Operating results for the three and six months ended December 31, 2006 are not necessarily indicative of the results that may be expected for the year ending June 30, 2007. For further information, refer to the financial statements and footnotes thereto as of and for the year ended June 30, 2006, included in the Annual Report on Form 10-K of Array BioPharma Inc. (the Company or Array) filed on September 1, 2006, with the Securities and Exchange Commission.

Use of Management's Estimates

The preparation of financial statements in conformity with U.S. generally accepted accounting principles requires management to make certain estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from those estimates.

Summary of Significant Accounting Policies

Cash Equivalents and Marketable Securities

Cash equivalents consist of short term, highly liquid financial instruments that are readily convertible to cash and have maturities of three months or less from the date of purchase and may consist of money market funds, taxable commercial paper, U.S. government agency obligations and corporate notes and bonds with high credit quality. Marketable securities consist of similar financial instruments with maturities of greater than three months.

At December 31, 2006 and June 30, 2006, management designated marketable securities held by the Company as available-for-sale securities for purposes of Statement of Financial Accounting Standards No. 115, *Accounting for Certain Investments in Debt and Equity Securities*. Securities available-for-sale are carried at fair value, with unrealized gains and losses reported as a component of stockholders' equity until their disposition. The amortized cost of debt securities in this category is adjusted for amortization of premiums and accretion of discounts to maturity. Such amortization is included in investment income. Realized gains and losses, declines in value judged to be other-than-temporary on securities available-for-sale and interest on securities available-for-sale are included in investment income. The cost of securities sold is based on the specific identification method.

Inventories

Inventories consist of individual chemical compounds in the form of Optimer® building blocks available-for-sale and commercially available fine chemicals used in the Company's proprietary drug discovery programs and research collaborations. Inventories are stated at the lower of cost or market, cost being determined under the first-in, first-out method. The Company reviews its chemical inventories periodically and writes down the carrying cost for non-marketability to estimated net realizable value through an appropriate reserve.

Deferred Rent

During July and August 2006, the Company terminated its existing facility leases and executed new lease agreements with a different landlord. Accordingly, the entire June 30, 2006 deferred rent balance of \$1.6 million was reversed and recorded as a reduction to the Company's recognized rent expense for the first quarter of fiscal 2007. Additionally, in conjunction with the assignment of facility purchase options as described in Note 4: Operating Leases, the Company received net proceeds of \$32.3 million which was recorded as deferred rent and is being recognized on a straight-line basis as a reduction to rent expense over the related ten-year term of the new facilities leases. The current facilities leases provide for annual rent increases, and the Company recognizes the average annual rent expense over the term of these leases on a straight-line basis. The current portion of the deferred rent balance reflected on the Company's balance sheet represents the amount of expected deferred rent credits to be applied as a reduction to the Company's rent expense over the next twelve-month period.

Revenue Recognition

Most of the Company's revenue is derived from designing, creating, optimizing, evaluating and developing drug candidates for its collaborators. The majority of collaboration revenue consists of fees received based on contracted annual rates for full time equivalent employees working on drug discovery programs. The Company's collaboration agreements also include license and up-front fees, milestone payments upon achievement of specified research or development goals and royalties on sales of resulting products. A small portion of the Company's revenue comes from fixed fee agreements and from sales of compounds on a per-compound basis.

Collaboration agreements typically call for a specific level of resources as measured by the number of full time equivalent scientists working a defined number of hours per year at a stated price under the agreement. The Company recognizes revenue under its collaboration agreements on a monthly basis as work is performed. The Company recognizes revenue from sales of Lead Generation Library and Optimizer building block compounds as the compounds are shipped, as these agreements are priced on a per-compound basis and title and risk of loss passes upon shipment to the Company's customers. In general, contract provisions include predetermined payment schedules or the submission of appropriate billing detail. Payments received in advance of performance are recorded as advance payments from collaborators until the revenue is earned.

Revenue from license fees and up-front fees is non-refundable and is recognized on a straight-line basis over the expected period of the related research program. Milestone payments are non-refundable and are recognized as revenue over the expected period of the related research program. A portion of each milestone payment is recognized when the milestone is achieved based on the applicable percentage of the research term that has elapsed. Any balance is recognized ratably over the remaining research term. Revenue recognition related to license fees, up-front payments and milestone payments could be accelerated in the event of early termination of programs.

The Company reports revenue for lead generation and lead optimization research, custom synthesis and process research, the development and sale of chemical compounds and the co-development of proprietary drug candidates it out-licenses, as collaboration revenue. License and milestone revenue is combined and reported separately from collaboration revenue.

Accounting for Share-Based Compensation

The Company follows the fair value method of accounting for share-based compensation arrangements in accordance with Financial Accounting Standards Board (FASB) Statement No. 123R, *Share-Based Payment* (SFAS 123R). The Company adopted SFAS 123R effective July 1, 2005 using the modified prospective method of transition. Under the modified prospective method of transition, compensation expense is recognized beginning with the effective date of adoption of SFAS 123R for all share-based payments (i) granted after the effective date of adoption and (ii) granted prior to the effective date of adoption and that remain unvested on the date of adoption. Share-based compensation arrangements covered by SFAS 123R currently include stock options granted under our Amended and Restated Stock Option and Incentive Plan (the Option Plan) and purchases of common stock by our employees at a discount to the market price during offering periods under our Employee Stock Purchase Plan (the ESPP).

Edgar Filing: ARRAY BIOPHARMA INC - Form 10-Q

Under SFAS 123R, the estimated fair value of share-based-compensation, including stock options granted under the Option Plan and purchases of common stock by employees at a discount to market price under the ESPP, is recognized as compensation expense. The estimated fair value of stock options is expensed on a straight-line basis over the expected term of the grant. Compensation expense for purchases under the ESPP is recognized based on the estimated fair value of the common stock during each offering period and the percentage of the purchase discount.

The Company recorded \$1.2 million (\$0.03 per share) and \$2.4 million (\$0.06 per share) of total share-based compensation expense for the three and six months ended December 31, 2006, respectively. For the three and six months ended December 31, 2005, share-based compensation expense was \$1.7 million (\$0.04 per share) and \$3.4 million (\$0.09 per share), respectively. These charges had no impact on the Company's cash flows. Share-based compensation expense (in thousands) is allocated among the following categories:

	Three Months Ended December 31,		Six Months Ended December 31,	
	2006	2005	2006	2005
Cost of revenue	\$ 262	\$ 546	\$ 591	\$ 1,071
Research and development for proprietary drug discovery	411	320	781	733
Selling, general and administrative expenses	518	799	1,021	1,607
Total	\$ 1,191	\$ 1,665	\$ 2,393	\$ 3,411

The Company has computed the estimated fair values of all share-based compensation using the Black-Scholes option pricing model and has applied the assumptions set forth in the following table.

	Average Risk-Free Interest Rate	Dividend Yield	Average Volatility	Weighted- Average Option Life (Years)
First six months of Fiscal Year 2007	4.63	% 0	% 71.7	% 6.3
First six months of Fiscal Year 2006	4.30	% 0	% 76.4	% 6.4

Beginning in fiscal year 2006, the Company calculated the estimated life of stock options granted using a simplified method, which uses the average of the vesting term and the actual term of the option, based on guidance from the SEC as contained in Staff Accounting Bulletin No. 107 permitting the initial use of this method. During the fourth quarter of 2006, the Company conducted a detailed evaluation of historical unexercised employee stock options that resulted in an estimated stock option life that was directly comparable to that calculated under the simplified method described above. The Company determined expected volatility for the periods presented using the historical method, which is based on the daily historical trading data of the Company's common stock from November 2000, the date of the Company's initial public offering, through the last day of the applicable accounting period. Management selected the historical method primarily because this method is recognized as a valid method used to predict future volatility, and management has not identified a more appropriate method.

The Black-Scholes option pricing model requires the input of highly subjective assumptions. Because the Company's employee stock options have characteristics significantly different from those of traded options, and because changes in the subjective input assumptions can materially affect the fair value estimate, in management's opinion, the existing models may not provide a reliable single measure of the fair value of its employee stock options or common stock purchased under the ESPP. In addition, management will continue to assess the assumptions and methodologies used to calculate estimated fair value of share-based compensation. Circumstances may change and additional data may become available over time, which may result in changes to these assumptions and methodologies, which could materially impact the Company's fair value determination.

Edgar Filing: ARRAY BIOPHARMA INC - Form 10-Q

A summary of activity in the Option Plan for the six-month period ended December 31, 2006 is as follows:

	Number of Option Shares	Weighted- Average Exercise Price
Outstanding Balance, June 30, 2006	7,595,492	\$ 6.63
Granted	498,890	8.83
Exercised	(617,628)	3.65
Forfeited or expired	(53,133)	7.74
Outstanding Balance, December 31, 2006	7,423,621	7.02
Exercisable shares as of December 31, 2006	4,639,403	7.03

As of December 31, 2006, there was \$9.8 million of unrecognized compensation expense related to unvested share-based compensation arrangements granted under the Option Plan. This expense (in thousands) is expected to be recognized as follows:

Fiscal Year

2007 - remaining periods	\$ 2,082
2008	3,558
2009	2,524
2010	1,499
2011	132
	\$ 9,795

Comprehensive Loss

A reconciliation (in thousands) of net loss to comprehensive loss is as follows:

	Three Months Ended December 31, 2006	2005	Six Months Ended December 31, 2006	2005
Net loss	\$ (15,872)	\$ (8,711)	\$ (24,103)	\$ (18,383)
Change in unrealized gain (loss) on marketable securities	47	10	221	(98)
Total comprehensive loss	\$ (15,825)	\$ (8,701)	\$ (23,882)	\$ (18,481)

Net Loss Per Share

Basic and diluted net loss per share has been computed by dividing net loss for the period by the weighted average number of common shares outstanding during the period. The Company has excluded the effects of outstanding stock options from the calculation of diluted net loss per share because all such securities are anti-dilutive for all periods presented. The number of common share equivalents relating to these stock options excluded from the diluted loss per share calculations for the three months ended December 31, 2006 and 2005 were 2,406,825 shares and 1,382,458 shares, respectively. For the six months ended December 31, 2006 and 2005 the number of common share equivalents were 1,847,463 shares and 1,380,623 shares, respectively.

Recent Accounting Pronouncements

In September 2006, the SEC released Staff Accounting Bulletin No. 108, *Considering the Effects of Prior Year Misstatements when Quantifying Misstatements in Current Year Financial Statements* (SAB 108). SAB 108 provides interpretive guidance on the SEC's views regarding the process of quantifying the materiality of financial statement misstatements. SAB 108 is effective for fiscal years ending after November 15, 2006. The Company adopted SAB 108 during the second quarter of fiscal 2007 and there was no impact on its financial position or results of operations.

Note 2: Cash, Cash Equivalents and Marketable Securities

Cash, cash equivalents and marketable securities classified as available-for-sale as of December 31, 2006 and June 30, 2006 consist of the following (in thousands):

	December 31, 2006	June 30, 2006
Cash and cash equivalents:		
Cash	\$ 904	\$ 449
Money market fund	7,970	15,119
Repurchase agreements	8,165	
Total	\$ 17,039	\$ 15,568
Marketable securities:		
Auction rate securities	\$ 36,600	\$ 17,528
Federal agency mortgage-backed securities	30,761	37,004
Total	\$ 67,361	\$ 54,532
Total cash, cash equivalents and marketable securities	\$ 84,400	\$ 70,100

Marketable securities at December 31, 2006 and June 30, 2006 are shown below (in thousands) by contractual maturity. Actual maturities may differ from contractual maturities because issuers of the securities may have the right to prepay obligations. Although auction rate securities bear maturity dates that are long-term and sometimes perpetual, the near-term reset dates have been used as the implied maturity dates for classifying these investments below.

	December 31, 2006	June 30, 2006
Marketable securities:		
Due in one year or less	\$ 63,295	\$ 44,132
Due after one year through two years	4,066	10,400
Total	\$ 67,361	\$ 54,532

The Company has included marketable securities due after one year within current assets, as these investments are available for use in current operating activities.

Note 3: Long Term Debt

The Company entered into a Loan and Security Agreement with Comerica Bank (Bank) on June 28, 2005, which was amended on July 7, 2006 (Loan and Security Agreement). The Loan and Security Agreement provides for a \$10 million term loan, up to \$5 million in equipment advances and a revolving line of credit, providing for up to \$6.75 million in standby letters of credit, all of which are secured by a security interest in the Company's assets, other than its intellectual property.

The full \$10 million term loan was advanced to the Company on June 30, 2005. As of September 2006, the Company had received the full \$5 million allotment of equipment advances which was used to finance the purchase of equipment, capitalized software and tenant improvements. Interest on these loans, currently having an interest rate of 6.5% per annum, is payable in monthly installments, with a balloon payment of \$15 million due on June 28, 2010.

During the first quarter of fiscal 2007, standby letters of credit were issued as required by the Company's new facilities leases in the amount of \$6.7 million. These standby letters of credit expire on August 31, 2016.

The Loan and Security Agreement contains representations and warranties and affirmative and negative covenants that are customary for credit facilities of this type. If the Company's total cash, cash equivalents and marketable securities, including those invested at the Bank, falls below \$40 million, between \$30 million and \$27.5 million, or below \$27.5 million, the Company must maintain minimum cash balances at the Bank of \$2 million, \$13 million or \$24 million, respectively. In addition, the Loan and Security Agreement could restrict the Company's ability to, among other things, sell certain assets, engage in a merger or change in control transaction, incur debt, pay cash dividends and make investments. The Loan and Security Agreement also contains events of default that are customary for credit facilities of this type, including payment defaults, covenant defaults, insolvency type defaults and events of default relating to liens, judgments, material misrepresentations and the occurrence of certain material adverse events.

Note 4: Operating Leases

Assignment and Facility Lease Agreements. On June 22, 2006, the Company entered into a series of agreements involving the assignment to BioMed Reality L.P. (BioMed) of options it acquired to purchase the facilities that it occupied in Boulder and Longmont, Colorado and the subsequent lease of those facilities from BioMed. Pursuant to an Assignment Agreement dated June 22, 2006 between Array and BioMed (the Assignment Agreement), BioMed agreed to purchase these facilities in both Boulder and Longmont and the Company assigned the option to purchase these facilities to BioMed for a total of \$30.5 million, payable upon the purchase of the Boulder and Longmont facilities by BioMed.

On July 7, 2006, BioMed completed the purchase of the Boulder facility as contemplated by the Assignment Agreement (the Boulder Closing) and paid the Company a total of \$16.5 million pursuant to the Assignment Agreement. As part of the transactions contemplated by the Assignment Agreement, the Company also entered into a lease agreement with BioMed, dated July 7, 2006, for the Boulder facility (the Boulder Lease). The Boulder Lease has a term of 10 years with an initial rental rate of \$4.8 million annually, subject to 2% annual increases, with the right to extend for up to two additional five-year terms. In addition, the Company received a tenant improvement allowance of \$1.7 million under the Boulder Lease. Upon the Boulder Closing, the prior lease agreements for the Boulder facility terminated.

On August 9, 2006, BioMed completed the purchase of the Longmont facility as contemplated by the Assignment Agreement (the Longmont Closing) and paid the Company a total of \$14.0 million pursuant to the Assignment Agreement. As part of the transactions contemplated by the Assignment Agreement, the Company also entered into a lease agreement with BioMed, dated August 9, 2006, for the Longmont facility (the Longmont Lease). The Longmont Lease has a term of 10 years with an initial rental rate of \$2.2 million annually, subject to 2% annual increases, with the right to extend for up to two additional five-year terms. In addition, the Company received a tenant improvement allowance of \$300,000 under the Longmont Lease. Upon the Longmont Closing, the prior lease agreements for the Longmont facility terminated.

The Company recorded the combined net proceeds from BioMed of \$32.3 million, net of approximately \$200,000 in transaction-related costs, as deferred rent. For more information see Note 1: Summary of Significant Accounting Policies Deferred Rent .

Note 5: Segment, Geographic and Concentration Information

All operations of the Company are considered to be in one operating segment and, accordingly, no segment disclosures have been presented. The physical location of the Company's property, plant and equipment is within the United States. The following table details revenue (in thousands) from customers by geographic area based on the country in which collaborators are located or the destination where compounds from the Company's inventories are shipped.

	Three Months Ended December 31,		Six Months Ended December 31,	
	2006	2005	2006	2005
North America	\$ 5,894	\$ 7,809	\$ 12,262	\$ 14,779
Europe	136	2,549	3,220	6,063
Japan and Asia-Pacific	1,528	1,582	3,102	2,340
Total revenue	\$ 7,558	\$ 11,940	\$ 18,584	\$ 23,182

Approximately 93% of the revenue generated from Europe during the six month period ended December 31, 2006 is related to a milestone payment received in the first quarter of fiscal 2007 in accordance with the Company's collaboration and licensing agreement with AstraZeneca AB, located in Sweden. No revenue associated with this agreement was recognized during the three-month period ended December 31, 2006. During the three and six months ended December 31, 2005, revenue from AstraZeneca represented 96% and 95%, respectively, of the revenue generated from Europe. For the three and six months ended December 31, 2006, revenue generated primarily from two Japanese collaborators represented 20% and 17%, respectively, of total revenue. For the three and six months ended December 31, 2005, revenue generated from these same two Japanese customers represented 13% and 10%, respectively, of total revenue. No other individual international country exceeded 10% of the Company's revenue for any of the periods presented.

During the six-month period ended December 31, 2006, revenue from four of the Company's customers represented approximately 39%, 25%, 16%, and 13% of total revenue, while three of the Company's customers represented approximately 33%, 25%, and 20% of total revenue for the comparative period in the prior fiscal year.

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations

The Management's Discussion and Analysis of Financial Condition and Results of Operations contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements about our expectations related to realizing new revenue streams and obtaining future collaboration agreements that include milestone and/or royalty payments, the success of our internal proprietary drug discovery activities, the expected level of our investment in proprietary research and our future headcount and capital expenditure requirements. These statements involve significant risks and uncertainties, including those discussed below and those described more fully in other reports filed by Array BioPharma with the Securities and Exchange Commission. Because these statements reflect our current expectations concerning future events, our actual results could differ materially from those anticipated in these forward-looking statements. The factors that could cause actual results to differ from our expectations include, but are not limited to, our ability to achieve and maintain profitability, the extent to which the pharmaceutical and biotechnology industries are willing to in-license drug candidates for their product pipelines and to collaborate with and fund third parties on their drug discovery activities, our ability to out-license our proprietary candidates on favorable terms, our ability to continue to fund and successfully progress internal research efforts and to create effective, commercially viable drugs, risks associated with our dependence on our collaborators for the clinical development and commercialization of our out-licensed drug candidates, the ability of our collaborators and of Array to meet objectives, including clinical trials, tied to milestones and royalties, our ability to attract and retain experienced scientists and management, and the risk factors contained in the Annual Report on Form 10-K filed by Array with the Securities and Exchange Commission (SEC) on September 1, 2006. We are providing this information as of the date of this report. We undertake no duty to update any forward-looking statements to reflect the occurrence of events or circumstances after the date of such statements or of anticipated or unanticipated events that alter any assumptions underlying such statements.

The following discussion of our financial condition and results of operations should be read in conjunction with the financial statements and notes to those statements included elsewhere in this report.

Overview

Array BioPharma is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat life threatening and debilitating diseases. Our proprietary drug development pipeline is primarily focused on the treatment of cancer and inflammatory disease and includes clinical candidates that are designed to regulate therapeutically important targets. In addition, leading pharmaceutical and biotechnology companies collaborate with Array to discover and develop drug candidates across a broad range of therapeutic areas.

We have identified multiple drug candidates in our own proprietary programs and in collaborations with other drug companies. We currently have four wholly-owned drugs in clinical development and are advancing a portfolio of discovery programs. We intend to progress our proprietary drug programs through clinical testing and continue to evaluate select programs for out-licensing opportunities with pharmaceutical and biotechnology partners.

We have built our drug development pipeline, and our discovery and development capabilities, primarily through cash flow from collaborations and through sales of our equity securities. Through December 31, 2006, we have recognized \$208.9 million in collaboration revenue, and we have received \$18.2 million in up-front payments and \$12.5 million in milestone payments from our collaborators and out-licensing partners. Under our existing collaboration agreements, we have the potential to earn over \$200.0 million in additional milestone payments if we achieve all of the drug discovery objectives under these agreements, as well as royalties on any resulting product sales from 15 different programs.

We have incurred net losses since inception and expect to incur losses in the near future as we continue to invest in our proprietary drug discovery programs. As of December 31, 2006, we had an accumulated deficit of \$157.8 million.

Revenue. We generate revenue through the out-licensing of select proprietary drug discovery programs for license and up-front fees, research funding based on the number of full-time equivalents contractually assigned to the program, and research and development milestone payments. We also have the potential to generate revenue

from royalties on future product sales. Four programs have been out-licensed to date to AstraZeneca, Genentech, Inc. and Amgen Inc., and we have received up-front license fees of \$18.2 million in total for these programs.

We also generate revenue through collaborations aimed at inventing drug candidates for our collaborators. We receive research funding based on the number of full-time equivalent employees contractually assigned to a program, plus related research expenses. Under certain of these agreements, we are entitled to receive additional payments based on the achievement of research milestones, drug development milestones and/or royalty payments based on sales of products created as a result of these collaborations.

We sell our Optimer® building blocks, which are the starting materials used to create more complex chemical compounds in the drug discovery process, on a per-compound basis without any restrictions on use. In addition, we have licensed our Lead Generation Libraries, which are a collection of structurally related chemical compounds that may have the potential of becoming drug candidates, on a non-exclusive basis to our collaborators for their internal research purposes. We are no longer developing new Lead Generation Libraries other than for our proprietary research and expect future revenue from sales of compounds in our Lead Generation Libraries to continue to be insignificant.

We report revenue for lead generation and lead optimization research, custom synthesis and process research, the development and sale of chemical compounds and the co-development of proprietary drug candidates we out-license, as collaboration revenue. License and milestone revenue is combined and reported separately from collaboration revenue.

Revenue Recognition. We recognize revenue under our collaboration agreements on a monthly basis as work is performed. Per-compound revenue is recognized as compounds are shipped. Revenue from license fees and up-front fees is recognized on a straight-line basis over the expected period of the related research program. Payments received in advance of performance are recorded as advance payments from collaborators until the revenue is earned. Milestone payments are non-refundable and are recognized as revenue over the expected period of the related research program. A portion of each milestone payment is recognized when the milestone is achieved based on the applicable percentage of the research term that has elapsed. Any balance is recognized ratably over the remaining research term. Revenue recognition related to license fees, up-front payments and milestone payments could be accelerated in the event of early termination of programs.

Customer Concentration. Our top 10 collaborators contributed approximately 98% of our total revenue for the first six months of fiscal 2007, and our current top four collaborators, Genentech, InterMune, Inc., AstraZeneca and Ono Pharmaceutical Co., Ltd., accounted for 39%, 25%, 16%, and 13%, respectively, of our total revenue. During the same period of fiscal year 2006, Genentech, AstraZeneca and InterMune, accounted for 33%, 25%, and 20%, respectively, of our total revenue. In general, our collaborators may terminate their collaboration agreements with us on 90 to 120 days prior notice.

International Revenue. International revenue represented 34% of our total revenue during the first six months of fiscal year 2007, down from 36% for the same period last year. Our international revenue is primarily attributable to European and Japanese collaborations. International revenue decreased in the first six months of fiscal year 2007 over the comparable prior year period due to the expiration of the research funding period of our collaboration with AstraZeneca in November 2005 of the prior fiscal year. All of our collaboration agreements are denominated in United States dollars.

Cost of Revenue. Cost of revenue represents research and development conducted for our collaborators and the cost of chemical compounds sold from our inventory. These costs consist mainly of compensation, fringe benefits, supplies, small tools, facilities, depreciation, recruiting and relocation and other direct and indirect laboratory support and collaboration related costs. Fine chemicals consumed as well as any required inventory reserve adjustments are also recorded as cost of revenue. We review the levels and values of our chemical inventories periodically and, when required, write down the carrying cost of our inventories for non-marketability to estimated net realizable value through an appropriate reserve.

Research and Development Expenses for Proprietary Drug Discovery. Research and development expenses for proprietary drug discovery consists of all costs associated with our proprietary drug development pipeline, including compensation and fringe benefits, consulting and outsourced services, laboratory supplies, and allocated facility costs and depreciation. When an internal proprietary program is out-licensed, all subsequent costs

of the out-licensed program are reported as cost of revenue.

Selling, General and Administrative Expenses. Selling, general and administrative expenses consist of compensation, fringe benefits, business development, accounting, information technology and administration costs, including patent prosecution, recruiting and relocation, consulting and professional services, travel and meals, advertising, sales commissions, facilities, depreciation and other office and management expenses.

Business Development. We currently license our compounds and enter into collaborations directly with pharmaceutical and biotechnology companies through opportunities identified by our business development group, senior management, scientists and customer referrals. In addition, we license our compounds and enter into collaborations in Japan through an agent.

Future Outlook. We plan to continue to increase our investment in proprietary research to broaden our product pipeline and to further enhance our clinical and regulatory capabilities to allow us to advance drugs further in clinical development. We will consider commercializing select programs ourselves while continuing to evaluate out-licensing opportunities to maximize the risk-adjusted return of our proprietary programs. As part of these efforts, we expect near term selling, general and administrative costs to rise in connection with increased patent and other intellectual property related costs incurred to protect and enforce our intellectual property rights in our proprietary programs. We also expect research and development for proprietary drug discovery costs to rise in connection with building our clinical and regulatory capabilities. As we devote more scientists to our proprietary research, we expect fewer scientists will be assigned to revenue generating collaborations and reported revenue will decline. Because of our strategy to retain other proprietary programs later in clinical development before out-licensing them or commercializing them ourselves, we may not recognize significant revenue from new out-licensing opportunities in the near term. Our current expectations concerning future events in this paragraph are subject to many risks and uncertainties, including many that are beyond our control. These risks are described more fully under the caption **Risk Factors** included in our annual report on Form 10-K filed with the SEC on September 1, 2006, and in other reports we file with the SEC.

Results of Operations

Three and Six Months Ended December 31, 2006 and 2005

Revenue. Collaboration revenue decreased by approximately \$1.7 million for the three months ended December 31, 2006, compared to the same period last year. For the six months ended December 31, 2006, collaboration revenue decreased by approximately \$2.0 million. The decline during the three and six month periods was the result of decreased collaboration revenue of \$1.9 million and \$3.8 million, respectively. These decreases were primarily attributed to research programs that expired during the prior fiscal year with AstraZeneca and Eli Lilly and Company and one of our programs with Takeda Chemical Industries, Ltd. Additionally, collaboration revenue from the sale of Lead Generation Libraries and Optimer building blocks decreased by approximately \$228,000 and \$665,000, respectively, during the same periods. Expanded programs with Genentech and the research collaboration with Ono that began in November 2006 partially offset these decreases and resulted in increased revenue of approximately \$490,000 and \$2.5 million, respectively.

License and milestone revenue decreased by \$2.7 million and \$2.6 million during the three and six months ended December 31, 2006, respectively, compared to the same periods last year. These decreases were due to the full recognition of previously received license and milestone payments from AstraZeneca and Genentech in November 2005, which were partially offset by a \$3.0 million milestone payment received from AstraZeneca during the first quarter of fiscal year 2007 for advancing ARRY-886 into Phase 2 clinical trials.

Share-Based Compensation. We follow the fair value method of accounting for share-based compensation arrangements in accordance with FASB Statement No. 123R, *Share-Based Payment* an amendment of FASB Statement No. 123 and 95 (SFAS 123R). We adopted SFAS 123R effective July 1, 2005 of the prior fiscal year using the modified prospective method of transition. We recorded \$1.2 million (\$0.03 per share) and \$2.4 million (\$0.06 per share) of share-based compensation expense for the three and six months ended December 31, 2006, respectively. For the same periods last year, we recorded \$1.7 million (\$0.04 per share) and \$3.4 million (\$0.09 per share), respectively. Share-based compensation expense is allocated among cost of revenue, research and development expenses for proprietary drug discovery and selling, general and administrative expenses based on the function of the related employee. This charge had no impact on our cash flows for the periods presented. For more

information about SFAS 123R, see Note 1: Summary of Significant Accounting Policies Accounting for Share-Based Compensation to the Unaudited Notes to Condensed Financial Statements included in this Form 10-Q, as well as the section below entitled Critical Accounting Policies Share-Based Compensation .

Cost of Revenue. Cost of revenue decreased by \$3.8 million, or 38%, and \$6.9 million, or 36% during the three and six months ended December 31, 2006, respectively, over the same periods last year. Cost of revenue as a percentage of collaboration revenue decreased to 82% and 80% for the three and six months ended December 31, 2006, respectively, compared with 108% and 111% for the same periods last year. These decreases were largely the result of increased average pricing received from collaborations for full-time equivalent scientists during the first half of fiscal 2007 resulting in fewer scientific resources used in generating the same approximate level of revenue. Additionally, share-based compensation expense charged to cost of revenue for the three and six months ended December 31, 2006, decreased by approximately \$284,000 and \$480,000, respectively, due to option shares that became fully vested in the prior fiscal year.

On June 22, 2006, we assigned options we owned to purchase our Boulder and Longmont, Colorado facilities to BioMed Realty L.P. (BioMed), which purchased those facilities in July and August 2006. We entered into new lease agreements for these facilities with BioMed over a ten-year lease term and began amortizing our leasehold improvement costs for these facilities over a ten-year life. (For more information see Note 4: Operating Leases , to the Unaudited Notes to Condensed Financial Statements). Prior to completing these transactions, we had determined that we were reasonably assured during fiscal 2006 that we would be vacating our Boulder facility at the end of the initial lease term in March 2008 and therefore amortized the cost of leasehold improvements for that facility over an approximate two-year life. This change in estimated useful life from two to ten years resulted in a decrease of approximately \$215,000 and \$405,000 in amortized leasehold improvement costs charged to cost of revenue for the three and six months ended December 31, 2006, respectively, compared to last year. This quarterly difference is expected to continue for the remainder of the fiscal year. In addition, during the first quarter of fiscal 2007, following termination of our prior facility leases and execution of new lease agreements with BioMed, we reversed and recorded the entire deferred rent balance of \$1.6 million associated with our prior facilities leases and listed as a current liability on June 30, 2006, as a reduction to our recognized rent expense. This resulted in a decrease to cost of revenue for the six months ended December 31, 2006 of approximately \$600,000.

Research and Development Expenses for Proprietary Drug Discovery. Research and development expenses for proprietary drug discovery increased by \$7.0 million, or 90%, and \$9.2 million, or 56%, during the three and six months ended December 31, 2006, respectively, compared to the same periods last year. This increase was primarily due to additional scientists and increased pharmacology studies supporting our expanded efforts to advance proprietary compounds into regulated safety testing and clinical trials. The most significant increase in costs came from outsourced pharmacology studies and clinical trial related expenses supporting the advancement of our ErB2/EGFR (ARRY-543), Mek for inflammation (ARRY-162), P38 (ARRY-797), KSP (ARRY-520) and other programs. We expect that proprietary research and development spending will continue to increase as we focus more resources on our proprietary drug discovery and development programs and advance our programs potentially through clinical development.

These increases were partially offset by reductions in leasehold improvement costs and rent expense allocated to research and development expenses as described in cost of revenue above. The change in estimated useful life of our leasehold improvements resulted in a reduction of amortization of leasehold improvement costs charged to research and development expenses for proprietary drug discovery for the three and six months ended December 31, 2006 of approximately \$200,000 and \$430,000, respectively. This quarterly difference is expected to continue for the remainder of the fiscal year. Additionally, the reversal of the prior year deferred rent balance resulted in a reduction to rent expense allocated to research and development expenses for proprietary drug discovery for the six months ended December 31, 2006 of approximately \$850,000.

Selling, General and Administrative Expenses. Selling, general and administrative expenses decreased by approximately \$96,000, or 3%, and \$581,000, or 9%, during the three and six months ended December 31, 2006, respectively, compared to the same periods last year. The decrease was primarily the result of decreased share-based compensation expense of approximately \$281,000 and \$586,000 for the three and six months ended December 31, 2006, respectively, from option shares that became fully vested in the prior fiscal year. As described in cost of revenue above, the change in estimated useful life of our leasehold improvements resulted in a reduction of amortization of leasehold improvement costs charged to selling, general and administrative expenses for the three and six months ended December 31, 2006 by approximately \$35,000 and \$75,000, respectively, and the reversal of

the prior year deferred rent balance resulted in a reduction to rent expense allocated to selling, general and administrative expenses for the six months ended December 31, 2006 of approximately \$100,000. Slightly offsetting all these decreases in selling, general and administrative expenses compared to prior year periods were increases in compensation and benefit related expenses.

Interest Expense. Interest expense increased to approximately \$249,000 and \$489,000 for the three and six months ended December 31, 2006, respectively, from approximately \$153,000 and \$282,000 in the same periods of the prior year due to higher floating interest rates on a higher outstanding long term debt balance.

Interest Income. Interest income increased to \$1.1 million and \$2.2 million for the three and six months ended December 31, 2006 from approximately \$696,000 and \$1.4 million in the same periods of the prior year due to higher investment interest rates earned on higher average cash and investment balances.

Liquidity and Capital Resources

We have historically funded our operations through revenue from our collaborations and the issuance of equity securities. As of December 31, 2006, cash, cash equivalents and marketable securities totaled \$84.4million compared with \$70.1 million at June 30, 2006.

Net cash used in operating activities was \$20.1 million for the six months ended December 31, 2006 compared to \$15.8 million in the same period last year. During the first six months of fiscal year 2007, our net loss of \$24.1 million was reduced by noncash charges of approximately \$5.6 million associated with depreciation and share-based compensation expense and increased by \$2.7 million of noncash deferred rent credits. For the first six months of fiscal year 2007, our net operating assets and liabilities, excluding cash, decreased by approximately \$1.1 million. This was primarily due to decreases in accounts receivable balances and increases in advance payments from collaborators which were partially offset by decreases in accounts payable and accrued compensation and benefits. Accounts receivable balances decreased by approximately \$989,000 due to the timing of receipts from our customers while accounts payable balances decreased by approximately \$398,000 due to lower outstanding amounts to vendors for various laboratory equipment and supplies. Accrued compensation and benefits decreased by approximately \$2.3 million primarily due to the payment of the fiscal year 2006 employee bonuses during the second quarter of fiscal 2007. Advance payments from collaborators increased by approximately \$2.9 million primarily due to an early advance payment from Genentech.

During the six months ended December 31, 2006, we received net proceeds of \$32.3 million from BioMed related to the assignment of purchase options of our Boulder and Longmont, Colorado facilities. We **invested approximately \$2.2 million in laboratory equipment, primarily for biology, drug metabolism and analytical research and development operations, as well as in various computer hardware and software.** Purchases of marketable securities used \$45.4 million, while proceeds from the sale and maturity of marketable securities provided \$32.8 million. Financing activities provided \$4.0 million consisting of approximately \$3.1 million resulting from the exercise of stock options under our stock option plan and the issuance of shares under our employee stock purchase plan, as well as approximately \$850,000 from the issuance of long term debt used to finance purchases of capital equipment.

As of December 31, 2006, we had a \$10 million term loan and \$5 million of equipment advances outstanding under our Loan and Security Agreement with Comerica Bank, which currently bear interest at the rate of 6.5% per annum. Interest on the loans is payable in monthly installments. A balloon payment of \$15 million is due at maturity of the loans on June 28, 2010. We also have a revolving line of credit in the amount of \$6.75 million to support outstanding standby letters of credit that have been issued in relation to our facilities leases. We have outstanding standby letters of credit of \$6.7 million to secure our obligations under our facilities leases which will expire on August 31, 2016.

Our future capital requirements will depend on a number of factors, including the rate at which we invest in proprietary research, the growth of our collaboration business and the amount of collaboration research funding we receive, the timing of milestone and royalty payments, if any, from our collaboration and out-licensed programs, our capital spending on new facilities and equipment, expenses associated with unforeseen litigation, regulatory changes, competition, technological developments, general economic conditions and the extent to which we acquire or invest in other businesses, products and technologies.

In addition, our future capital requirements may be impacted if we do not receive potential milestone or royalty payments under our existing or future collaboration agreements. Our ability to realize these payments is subject to a number of risks, many of which are beyond our control and include the following: the drug development process is risky and highly uncertain, and we or our collaborators may not be successful in commercializing drug candidates we create; our collaborators have substantial control and discretion over the timing and continued development and marketing of drug candidates we create; the sale and manufacture of drug candidates we develop may not obtain regulatory approval; and, if regulatory approval is received, drugs we develop will remain subject to regulation or may not gain market acceptance, which could delay or prevent us from generating milestone or royalty revenue from the commercialization of these drugs.

We believe that our existing cash, cash equivalents and marketable securities and anticipated cash flow from existing collaboration agreements will be sufficient to support our current operating plan for at least the next 12 months. This estimate of our future capital requirements is a forward-looking statement that is based on assumptions that may prove to be wrong and that involve substantial risks and uncertainties. Our actual future capital requirements could vary as a result of a number of factors, including:

- the progress of our research activities;
- our ability to enter into agreements to out-license and co-develop our proprietary drug candidates, and the timing of those agreements in each candidate's development stage;
- the number and scope of our research programs;
- the progress of our preclinical and clinical development activities;
- the number and scope of phase 2 clinical trials we may decide to run;
- the progress of the development efforts of our collaborators;
- the availability of resources for revenue generating collaborations as we devote more resources to our proprietary programs;
- our ability to establish and maintain current and new collaboration agreements;
- the ability of our collaborators to fund research and development programs;
- the costs involved in enforcing patent claims and other intellectual property rights;
- the costs and timing of regulatory approvals; and
- the costs of establishing clinical development and distribution or commercialization capabilities.

Until we can generate sufficient levels of cash from our operations, which we do not expect to achieve in the foreseeable future, we expect to continue to utilize our existing cash and marketable securities resources that were primarily generated from the proceeds of our equity offerings. In addition, we may finance future cash needs through the sale of equity securities, strategic collaboration agreements and debt financing. We cannot assure that we will be successful in obtaining new or in retaining existing out-license or collaboration agreements, in securing agreements for the co-development of our proprietary drug candidates, or in receiving milestone and/or royalty payments under those agreements, that our existing cash and marketable securities resources will be adequate or that additional financing will be available when needed or that, if available, this financing will be obtained on terms favorable to us or our stockholders. Insufficient funds may require us to delay, scale back or eliminate some or all of our research or development programs or to relinquish greater or all rights to product candidates at an earlier stage of development or on less favorable terms than we would otherwise choose, or may adversely affect our ability to operate as a going concern. If we raise additional funds by issuing equity securities, substantial dilution to existing stockholders may result.

Obligations and Commitments

The following table shows our contractual obligations and commitments as of December 31, 2006 (in thousands).

	Payments due by period				Total
	Less than 1 year	1-3 years	4-5 years	After 5 years	
Operating lease obligations	\$ 7,199	\$ 14,585	\$ 15,071	\$ 36,426	\$ 73,281
Purchase obligations	9,396	1,015	13		10,424
Debt obligations (including interest, using current rate of 6.5%)	975	1,950	15,488		18,413
Total obligations	\$ 17,570	\$ 17,550	\$ 30,572	\$ 36,426	\$ 102,118

We are obligated under noncancelable operating leases for our facilities and, to a much smaller degree, certain office equipment. The original lease terms for our facilities are ten years, with renewal options for two additional five-year terms, and provide for annual 2% rent increases and generally require us to pay a proportionate share of real estate taxes, insurance, common area and other operating costs. Office equipment leases generally range from three to five years.

Purchase obligations totaling \$10.4 million were primarily for outsourced pharmacology services, chemicals, laboratory equipment and supplies.

During the first quarter of fiscal 2007, standby letters of credit were issued in relation to our facilities leases in the amount of \$6.7 million. These standby letters of credit expire on August 31, 2016 and are fully supported by a revolving line of credit with Comerica Bank.

Critical Accounting Policies

We believe critical accounting policies are essential to the understanding of our results of operations and require our management to make significant judgments in preparing the financial statements included in this report. Management has made estimates and assumptions based on these policies. We do not believe that materially different amounts would be reported if different assumptions were used. However, the application of these policies involves judgments and assumptions as to future events and, as a result, actual results could differ. The impact and any associated risks related to these policies on our business operations is discussed throughout Management's Discussion and Analysis of Financial Condition and Results of Operations where such policies affect our reported and expected financial results.

Revenue Recognition

We believe our revenue recognition policy is significant because the amount and timing of revenue is a key component of our results of operations. We follow the guidance of Staff Accounting Bulletin No. 104, which requires that a series of criteria be met in order to recognize revenue related to the performance of services or the shipment of products. If these criteria are not met, the associated revenue is deferred until the criteria are met. We recognize revenue when (a) persuasive evidence of an arrangement exists, (b) products are delivered or services are rendered, (c) the sales price is fixed or determinable and (d) collectibility is assured.

Most of our revenue is derived from designing, creating, optimizing, evaluating and developing drug candidates for our collaborators. The majority of our collaboration revenue consists of fees received based on contracted annual rates for full time equivalent employees working on a project. Our collaboration agreements also include license and up-front fees, milestone payments upon achievement of specified research or development goals and royalties on sales of resulting products. A small portion of our revenue comes from fixed fee agreements and from sales of compounds on a per-compound basis.

Our collaboration agreements typically call for a specific level of resources as measured by the number of full time equivalent scientists working a defined number of hours per year at a stated price under the agreement. We recognize revenue under our collaboration agreements on a monthly basis as work is performed. We recognize revenue from sales of Lead Generation Library and Optimizer building block compounds as the compounds are shipped, as these agreements are priced on a per-compound basis and title and risk of loss passes upon shipment to our customers.

Revenue from license fees and up-front fees is non-refundable and is recognized on a straight-line basis over the expected period of the related research program. Milestone payments are non-refundable and are recognized as revenue over the expected period of the related research program. A portion of any milestone payment is recognized at the date the milestone is achieved which is determined using the applicable percentage of the research term that has elapsed at the date the milestone is achieved. Any balance is recognized ratably over the remaining research term. Revenue recognition related to license fees, up-front payments and milestone payments could be accelerated in the event of early termination of programs.

In general, contract provisions include predetermined payment schedules or the submission of appropriate billing detail. Payments received in advance of performance are recorded as advance payments from collaborators until the revenue is earned.

We report revenue for lead generation and lead optimization research, custom synthesis and process research, the development and sale of chemical compounds and the co-development of proprietary drug candidates we out-license, as collaboration revenue. License and milestone revenue is combined and reported separately from collaboration revenue.

Share-Based Compensation

During the first quarter of the prior fiscal year, we adopted the fair value method of accounting for share-based awards using the modified-prospective method of transition as outlined in Financial Accounting Standards Board Statement No. 123R, *Share-Based Payment* (SFAS 123R). Under SFAS 123R, the estimated fair value of share-based-compensation, including stock options granted under our Stock Option Plan and purchases of common stock by employees at a discount to market price under the Employee Stock Purchase Plan (the ESPP) is recognized as compensation expense. The estimated fair value of stock options is expensed on a straight-line basis over the expected term of the grant. Compensation expense for purchases under the ESPP is recognized based on the estimated fair value of the common stock during each offering period and the percentage of the purchase discount.

Under SFAS 123R, we use the Black-Scholes option pricing model to estimate the fair value of the share-based awards as of the grant date. The Black-Scholes model, by its design, is highly complex, and dependent upon key data inputs estimated by management. The primary data inputs with the greatest degree of judgment are the estimated lives of the share-based awards and the estimated volatility of our stock price. The Black-Scholes model is highly sensitive to changes in these two data inputs. We calculated the estimated life of stock options granted using a simplified method, which is based on the average of the vesting term and the term of the option, as a result of guidance from the SEC as contained in Staff Accounting Bulletin No. 107 permitting the initial use of this method. During the fourth quarter of 2006, we conducted a detailed evaluation of historical unexercised employee stock options that resulted in an estimated stock option life that was directly comparable to that calculated under the simplified method described above. We determined expected volatility for the first two quarters of fiscal 2007 using the historical method, which is based on the daily historical trading data of our common stock from November 2000, the date of our initial public offering, through the last day of the applicable accounting period. Management selected the historical method primarily because we have not identified a more reliable or appropriate method to predict future volatility. For more information about the adoption of SFAS 123R, see Note 1: Summary of Significant Accounting Policies Accounting for Share-Based Compensation to the Unaudited Notes to Condensed Financial Statements included in this Form 10-Q.

Recent Accounting Pronouncements

For a summary of a recent accounting pronouncement, see Note 1: Summary of Significant Accounting Policies Recent Accounting Pronouncements to the Unaudited Notes to Condensed Financial Statements included in this Form 10-Q.

Item 3. Quantitative and Qualitative Disclosures About Market Risk

Interest Rate Risk. Our interest income is sensitive to changes in the general level of United States interest rates, particularly since a significant portion of our investments are and will be in short term marketable securities. Due to the nature and short term maturities of our short term investments, we have concluded that there is no material market risk exposure. Based on outstanding investment balances at December 31, 2006, a change of 100 basis points in interest rates would result in a change in our annual interest income of approximately \$844,000.

We are also impacted by adverse changes in interest rates relating to variable-rate borrowings under our credit facility. We pay interest on advances under our loan agreement at one of three variable rates, which are adjusted periodically for changes in the underlying prevailing rate. Changes in prevailing interest rates will not affect the fair value of our debt, but would impact future results of operations and cash flows. At December 31, 2006, we had \$15 million of long term debt outstanding and the interest rate on our term loan and equipment advances was 6.5%. This rate is adjusted based on changes in the bank's prime lending rate. Assuming constant debt levels, a change of 100 basis points in our interest rate would result in a change in our annual interest expense of approximately \$150,000.

Foreign Currency Rate Fluctuations. All of our collaboration agreements and purchase orders are denominated in United States dollars. Therefore, we are not exposed to direct changes in foreign currency exchange rates.

Inflation. We do not believe that inflation has had a material impact on our business or operating results during the periods presented.

Item 4. Controls and Procedures

Under the supervision and with the participation of our Chief Executive Officer, Chief Financial Officer and other senior management personnel, we evaluated the effectiveness of the design and operation of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934). Based on that evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that these disclosure controls and procedures as of December 31, 2006 are effective in recording, processing, summarizing and reporting the financial results of the Company's operations. There were no changes in our internal controls and procedures over financial reporting during the quarter ended December 31, 2006 that have materially affected, or are reasonably likely to materially affect, the internal control over financial reporting.

PART II**Item 4. Submission of Matters to a Vote of Security Holders**

The annual meeting of the Company's stockholders was held on November 2, 2006. At that meeting, three proposals were submitted to a vote of the Company's stockholders. Proposal 1 was a proposal to elect three Class III directors to serve a three-year term of office expiring on the date of the 2009 annual meeting of stockholders. The three nominees for Class III director were Francis J. Bullock, Ph.D., Kevin Koch, Ph.D., and Douglas E. Williams, Ph.D. Proposal 2 was a proposal to approve two amendments to the Array BioPharma Inc. Employee Stock Purchase Plan. The amendments would register 450,000 additional shares for issuance under the plan and remove the requirement that employees be employed for at least 30 days as of the beginning of the offering period to be eligible to participate in the plan. Proposal 3 was a proposal to ratify the appointment of KPMG LLP as the Company's independent auditors for the fiscal year ending June 30, 2007. For further information regarding the annual meeting, including the terms of office of the directors remaining in office following the meeting, please see the Company's Proxy Statement on Schedule 14A filed with the Securities and Exchange Commission on September 28, 2006. The stockholders approved the proposals as follows:

Proposal	Number of Votes		Abstain/ Withhold
	For	Against	
Proposal 1 - Election of Class III directors			
Francis J. Bullock, Ph.D.	34,891,979		1,009,368
Kevin Koch, Ph.D.	35,612,349		288,998
Douglas E. Williams, Ph.D.	34,944,027		956,520
Proposal 2 - Approval of amendments to the Company's Employee Stock Purchase Plan	22,780,551	1,457,161	13,244
Proposal 3 - Ratification of the appointment of KPMG LLP	35,799,823	96,034	5,488

Item 6. Exhibits

- (a) Exhibits
- 10.1 Description of Performance Bonus Program (filed as an exhibit to the Registrant's current report on Form 8-K filed on November 2, 2006 (File No. 000-31979))
- 31.1 Certification of Robert E. Conway pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
- 31.2 Certification of R. Michael Carruthers pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
- 32.0 Certifications of Robert E. Conway and R. Michael Carruthers pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

Items 1, 2, 3 and 5 of Part II are not applicable and have been omitted.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Boulder, State of Colorado.

ARRAY BIOPHARMA INC.

Dated: February 5, 2007

By: /s/ Robert E. Conway
Robert E. Conway
Chief Executive Officer

Dated: February 5, 2007

By: /s/ R. Michael Carruthers
R. Michael Carruthers
Chief Financial Officer
(Principal Financial and Accounting Officer)

23
